The use of GLP-2 and related growth factors in intestinal diseases

    Research output: Contribution to journalReview articlepeer-review

    18 Citations (Scopus)


    The pharmacological application of intestinal growth factors has been recognized because of the protective and reparative actions of these factors in the intestinal tract. This review highlights the use of keratinocyte growth factor (KGF), IGF-1 and glucagon-like peptide 2 (GLP-2) in efficacy studies of intestinal damage; the results from these studies support potential clinical applications of these factors in treating intestinal diseases. In particular, GLP-2 has been assessed in preclinical and clinical investigations for its capacity to prevent or treat an increasing number of intestinal diseases, including short bowel syndrome, chemotherapy-induced intestinal mucositis and inflammatory bowel disease.

    Original languageEnglish
    Pages (from-to)440-446
    Number of pages7
    JournalCurrent Opinion in Investigational Drugs
    Issue number4
    Publication statusPublished - Apr 2010


    • GLP-2
    • Glucagon-like peptide 2
    • Growth factor
    • IGF-1
    • Inflammatory bowel disease
    • Keratinocyte growth factor
    • KGF
    • Mucositis
    • Short bowel syndrome


    Dive into the research topics of 'The use of GLP-2 and related growth factors in intestinal diseases'. Together they form a unique fingerprint.

    Cite this